Efficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort

First line HAART with tenofovir DF (TDF) and emtricitabine (FTC) in pivotal trials has been associated with high efficacy and good tolerability. However, real-life clinical practice often differs from clinical trials due to co-morbidities, co-infections, and less intensive clinical monitoring. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P12 Cite this article as: van Lunzen et al.: Efficacy and safety of TDF/FTCcontaining, first-line HAART in clinical practice: 3-year data from the German outpatient cohort. Journal of the International AIDS Society 2010 13(Suppl 4):P12. Full text: BioMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112894/